Baltimore Gas and Electric CEO to leave role for leadership position at parent company Excelon
Carim Khouzami, CEO of Baltimore Gas and Electric, will leave his position to take a leadership position at Excelon, BGE's parent company.
The leadership changes come amid ongoing criticisms of the company.
In recent months, Maryland leaders and ratepayers have called for a resolution to rising energy costs. Many BGE customers reported major increases in their energy bills, with some residents noting that their bills had doubled compared to the previous year. BGE stated that the increases stem from the need to improve aging infrastructure, increases in energy use—particularly due to cold weather, and the rising cost for the Empower Maryland efficiency program.PSC releases report detailing fraudulent inspections
On Tuesday, the Maryland Public Service Commission
released a report
alleging that a former BGE employee did not conduct proper inspections of gas infrastructure work and submitted falsified records over four years.
According to the PSC report, BGE did not provide a list of jobs affected by the falsified inspections nor performed targeted remediation or verification work on the pipeline segments in question.
On Wednesday, Baltimore City Council President Zeke Cohen responded by
calling for an oversight hearing
, emphasizing concerns about resident safety and BGE's accountability.
"We are extremely concerned about the way our residents have been treated in the city of Baltimore," Cohen said Wednesday. "You can't sit there and tell me and the Baltimore City Council that your top priority is safety when we then hear you have an inspector who is not doing their job."
Cohen has been vocal in advocating for reduced energy costs. Last month, he joined other city council members in calling for a halt to BGE's
planned 2026 rate increase
.
Earlier this month, lawmakers passed the
Next Generation Energy Act
, a bill aimed at reducing utility costs statewide. This legislation mandates specific spending on gas pipelines and directs the Public Service Commission to halt plans for multi-year rate increases that do not benefit customers. Furthermore, it prohibits utilities from charging ratepayers for certain expenses, including trade association memberships and private planes.
"Yesterday, members of the City Council sent a letter to BGE demanding answers about safety concerns," Cohen said in a statement Thursday. "Today, we learned that BGE's CEO Carim Khouzami will be leaving the utility for a role at Exelon. The Council's focus remains the same: we need real rate relief for our residents."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
Axiom Intelligence Acquisition Corp 1 Announces Completion of $200 Million Initial Public Offering
New York, New York, June 20, 2025 (GLOBE NEWSWIRE) — Axiom Intelligence Acquisition Corp 1 (NASDAQ:AXINU) (the 'Company') today announced the closing of its initial public offering of 20,000,000 units, which includes 2,500,000 units sold pursuant to the partial exercise of the underwriters' over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The Company's units commenced trading on the Nasdaq Global Market ('Nasdaq') under the symbol 'AXINU' on June 18, 2025. Each unit issued in the offering consists of one Class A ordinary share of the Company and one right to receive one tenth (1/10) of one Class A ordinary share upon the consummation of the Company's initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under the symbols 'AXIN' and 'AXINR,' respectively. The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, the Company intends to focus its initial search on companies in the European infrastructure industry. The Company's management team is led by Richard Dodd, its Executive Chairman, Douglas Ward, its Chief Executive Officer, Daniel Mamadou-Blanco, its President, Robert Dilling, its Chief Financial Officer, and Chris Ackermann, its Chief Operating Officer. Dr. Claire Handby, Steven Leighton and Christopher Ellis are the Company's independent directors and Sankalp Shangari and Wendy Li are its senior advisers. Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, acted as the lead book-running manager for the offering. Seaport Global Securities LLC acted as joint book-runner. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on June 17, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus, copies of which may be obtained from Cohen & Company Capital Markets, 3 Columbus Circle, 24th Floor, New York, NY 10019, Attention: Prospectus Department, or by email at: [email protected]. Copies of the registration statement can be accessed for free through the SEC's website at Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the anticipated use of the net proceeds of the offering and the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law. Contact Information: Axiom Intelligence Acquisition Corp 1Richard Dodd, Executive Chairman / Doug Ward, Chief Executive Officer [email protected] +44 20 3973 7928
Yahoo
2 days ago
- Yahoo
Liver-Assessment Tool Hepatoscope® Steadily Expands Installed-Base Validating Its Clinical and Commercial Viability
E-Scopics' Ultraportable, Software-Based Hepatoscope In Use Across Leading Institutions and Clinics AIX-EN-PROVENCE, France, June 20, 2025--(BUSINESS WIRE)--After successfully exhibiting its unique software-based liver assessment tool Hepatascope at the DDW Convention in San Diego and the EASL Conference in Amsterdam, the France-based medical ultrasound company E-Scopics will demonstrate the technology at the June 2025 American Diabetes Association Conference in Chicago. The technology is seeing expanded adoption, with the company reporting that it has established the technology in a number of important sites in the US and Europe, validating its clinical and commercial viability. In the span of a few short years, the company has successfully adapted its premium ultrafast imaging point-of-care systems into GI and primary care, putting the system into the hands of a growing number of users who recognize its clinical value and importance in improving the standard of care for patients. In the process, E-Scopics has completely disrupted the field of portable ultrasound by leveraging proprietary technology using software-based image reconstruction. In 2023 E-Scopics began to commercialize its first product, Hepatoscope, both in the USA and in EMEA countries. The company's mid-term goal is to increase its footprint globally, starting its expansion to most European countries, where patients at risk of chronic liver diseases are. Hepatoscope continues to gain recognition as an alternative to legacy technology, from major institutions and all-size healthcare institutions across the USA. E-Scopics Founder and CEO Claude Cohen-Bacrie, who brings deep experience developing and taking to market cutting-edge ultrasound technologies, commented, "Our ambition is to bring premium quantitative ultrasound modalities and tools at the point-of-care, in the hands of non-ultrasound expert users, for the benefit of healthcare systems and patients. Making patients' journey and care pathways simpler and more efficient is our priority. We are so pleased that our backers- both leading users who understand the clinical and business partners who get the commercial potential, are in it for the long haul- and really excited about it." The company recognized MASLD was on the rise globally, and the need to bring the healthcare community a less expensive, more portable, and easier-to-use tool to accurately screen for the disease. It was very deliberate, developing a tool that was simple to use and reducing costs. The Hepatoscope application can easily be loaded onto a consumer laptop or tablet and rapidly deployed in the field. In addition to ease-of-use, the company saw Ultrasound-as-a-Service model as means to open access to any clinic via an affordable monthly or pay-per-use subscription, innovating on the business side. Cohen-Bacrie continued, "We see a healthier patient population coming out of a world where there is healthy business competition which drives innovation. We would not be talking about elastography outside of this important competitive environment. Especially where liver assessment is concerned, patients really need it, clinicians are asking for better and more affordable tools, and the FDA and payers endorse it." The numbers bear the need out. Approximately 1.5 million patients have been diagnosed with metabolic dysfunction associated steatohepatitis (MASH) in the U.S., and it is estimated that the precursor to MASH—metabolic dysfunction-associated steatotic liver disease or MASLD—will affect more than half of all American adults by 2040. The MASLD spectrum ranges from a simple, generally nonprogressive fat buildup in the liver all the way to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually. Therefore, it is crucial to identify these patients and take care of them as early as possible. "As consumers we've become conditioned to expect the latest and greatest personal computing and communications tools, they simply make us more efficient in day-to-day tasks, said Dr. Julio Gutierrez, Associate Professor of Medicine at Scripps Center for Organ Transplant in La Jolla, CA and an early adopter of Hepatoscope. "I think of E-Scopics like Apple and have come to expect continuous innovation, and the clinical impact has been significant." Dr. Cyrielle Caussy MD, PhD, Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France, asserted, "In the endocrine and diabetology practice, approximately 80% of patients screened show low liver stiffness, which means they can be reassured without further referral or testing. By reducing the time between initial screening and specialty care, the Hepatoscope improves both the efficiency and quality of patient management. For high-risk patients, we can initiate care pathways much earlier, potentially slowing or halting the progression of liver disease. At the same time, for low-risk individuals, we avoid unnecessary referrals, which frees up resources and improves overall healthcare system efficiency. Importantly, patients appreciate the immediate feedback they receive, which encourages compliance with treatment plans and lifestyle modifications." E-Scopics will demonstrate Hepatoscope at the American Diabetes Association annual conference in Chicago in Booth #3527. Visitors may walk in and also book a time by emailing About E-Scopics: E-Scopics S.A.S is a MedTech company headquartered in France. The company advances the accessibility, affordability, and ease of use of premium ultrasound tools at the point of care. Its agile software platform has dematerialized and automated ultrasound imaging technologies. Ultrasound-as-a-Service products derived from this platform are specific Apps commercialized with pay-per-use or subscription business models. The company's first product, the Hepatoscope, leverages quantitative imaging capabilities to help any clinician assess liver fibrosis and steatosis—important markers of MASLD-MASH—non-invasively at the bedside. To learn more, visit View source version on Contacts Dan ConleyBeacon Communicationsdconley@ 312-593-8461 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business Wire
Liver-Assessment Tool Hepatoscope® Steadily Expands Installed-Base Validating Its Clinical and Commercial Viability
AIX-EN-PROVENCE, France--(BUSINESS WIRE)--After successfully exhibiting its unique software-based liver assessment tool Hepatascope at the DDW Convention in San Diego and the EASL Conference in Amsterdam, the France-based medical ultrasound company E-Scopics will demonstrate the technology at the June 2025 American Diabetes Association Conference in Chicago. The technology is seeing expanded adoption, with the company reporting that it has established the technology in a number of important sites in the US and Europe, validating its clinical and commercial viability. In the span of a few short years, the company has successfully adapted its premium ultrafast imaging point-of-care systems into GI and primary care, putting the system into the hands of a growing number of users who recognize its clinical value and importance in improving the standard of care for patients. In the process, E-Scopics has completely disrupted the field of portable ultrasound by leveraging proprietary technology using software-based image reconstruction. In 2023 E-Scopics began to commercialize its first product, Hepatoscope, both in the USA and in EMEA countries. The company's mid-term goal is to increase its footprint globally, starting its expansion to most European countries, where patients at risk of chronic liver diseases are. Hepatoscope continues to gain recognition as an alternative to legacy technology, from major institutions and all-size healthcare institutions across the USA. E-Scopics Founder and CEO Claude Cohen-Bacrie, who brings deep experience developing and taking to market cutting-edge ultrasound technologies, commented, 'Our ambition is to bring premium quantitative ultrasound modalities and tools at the point-of-care, in the hands of non-ultrasound expert users, for the benefit of healthcare systems and patients. Making patients' journey and care pathways simpler and more efficient is our priority. We are so pleased that our backers- both leading users who understand the clinical and business partners who get the commercial potential, are in it for the long haul- and really excited about it.' The company recognized MASLD was on the rise globally, and the need to bring the healthcare community a less expensive, more portable, and easier-to-use tool to accurately screen for the disease. It was very deliberate, developing a tool that was simple to use and reducing costs. The Hepatoscope application can easily be loaded onto a consumer laptop or tablet and rapidly deployed in the field. In addition to ease-of-use, the company saw Ultrasound-as-a-Service model as means to open access to any clinic via an affordable monthly or pay-per-use subscription, innovating on the business side. Cohen-Bacrie continued, 'We see a healthier patient population coming out of a world where there is healthy business competition which drives innovation. We would not be talking about elastography outside of this important competitive environment. Especially where liver assessment is concerned, patients really need it, clinicians are asking for better and more affordable tools, and the FDA and payers endorse it.' The numbers bear the need out. Approximately 1.5 million patients have been diagnosed with metabolic dysfunction associated steatohepatitis (MASH) in the U.S., and it is estimated that the precursor to MASH—metabolic dysfunction-associated steatotic liver disease or MASLD—will affect more than half of all American adults by 2040. The MASLD spectrum ranges from a simple, generally nonprogressive fat buildup in the liver all the way to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually. Therefore, it is crucial to identify these patients and take care of them as early as possible. 'As consumers we've become conditioned to expect the latest and greatest personal computing and communications tools, they simply make us more efficient in day-to-day tasks, said Dr. Julio Gutierrez, Associate Professor of Medicine at Scripps Center for Organ Transplant in La Jolla, CA and an early adopter of Hepatoscope. 'I think of E-Scopics like Apple and have come to expect continuous innovation, and the clinical impact has been significant.' Dr. Cyrielle Caussy MD, PhD, Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France, asserted, 'In the endocrine and diabetology practice, approximately 80% of patients screened show low liver stiffness, which means they can be reassured without further referral or testing. By reducing the time between initial screening and specialty care, the Hepatoscope improves both the efficiency and quality of patient management. For high-risk patients, we can initiate care pathways much earlier, potentially slowing or halting the progression of liver disease. At the same time, for low-risk individuals, we avoid unnecessary referrals, which frees up resources and improves overall healthcare system efficiency. Importantly, patients appreciate the immediate feedback they receive, which encourages compliance with treatment plans and lifestyle modifications.' E-Scopics will demonstrate Hepatoscope at the American Diabetes Association annual conference in Chicago in Booth #3527. Visitors may walk in and also book a time by emailing About E-Scopics: E-Scopics S.A.S is a MedTech company headquartered in France. The company advances the accessibility, affordability, and ease of use of premium ultrasound tools at the point of care. Its agile software platform has dematerialized and automated ultrasound imaging technologies. Ultrasound-as-a-Service products derived from this platform are specific Apps commercialized with pay-per-use or subscription business models. The company's first product, the Hepatoscope, leverages quantitative imaging capabilities to help any clinician assess liver fibrosis and steatosis—important markers of MASLD-MASH—non-invasively at the bedside. To learn more, visit
